According to the Zhitong Finance APP, HWHG (600079.SH) announced that its controlling subsidiary Yichang HWHG Pharmaceutical Co., Ltd. (hereinafter referred to as &#34;Yichang HWHG,&#34; in which the company holds an 80% stake) recently received the &#34;Drug Registration Certificate&#34; for Fluorobiphenyl Ester Injection approved by the National Medical Products Administration.
Fluorobiphenyl Ester Injection, as a non-steroidal analgesic using lipid microspheres as a drug carrier, is suitable for postoperative and cancer pain relief. The approval of Fluorobiphenyl Ester Injection marks the company's qualification to sell this drug in the domestic market. This product further enriches the company's product pipeline, and its market launch will have a positive impact on the company

600079

HWHG's subsidiary Yichang HWHG Pharmaceutical recently obtained the "Drug Registration Certificate" for Fluorobiphenyl Ester Injection approved by the National Medical Products Administration. This drug is a non-steroidal analgesic, suitable for postoperative and cancer pain relief. Its approval will enrich the company's product line and have a positive impact on the company

HWHG: Flurbiprofen Ester Injection has obtained a drug registration certificate